Merck KGaA (FRA:MRK) Given a €108.00 Price Target by Sanford C. Bernstein Analysts
Sanford C. Bernstein set a €108.00 ($125.58) target price on Merck KGaA (FRA:MRK) in a research report sent to investors on Thursday, Borsen Zeitung reports. The brokerage currently has a neutral rating on the healthcare company’s stock.
MRK has been the subject of several other reports. Credit Suisse Group set a €110.00 ($127.91) target price on Merck KGaA and gave the stock a buy rating in a research note on Friday, September 6th. DZ Bank reissued a buy rating on shares of Merck KGaA in a research note on Wednesday, August 14th. Kepler Capital Markets set a €108.00 ($125.58) price objective on Merck KGaA and gave the stock a buy rating in a research report on Monday, June 17th. Barclays set a €82.00 ($95.35) price objective on Merck KGaA and gave the stock a sell rating in a research report on Wednesday, August 14th. Finally, UBS Group set a €99.00 ($115.12) price objective on Merck KGaA and gave the stock a neutral rating in a research report on Thursday, August 8th. One equities research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and five have given a buy rating to the stock. The stock presently has an average rating of Hold and a consensus target price of €100.94 ($117.38).
MRK traded up €1.66 ($1.93) on Thursday, hitting €99.02 ($115.14). 739,433 shares of the company were exchanged. Merck KGaA has a twelve month low of €76.60 ($89.07) and a twelve month high of €115.00 ($133.72). The firm has a 50-day moving average price of €94.72 and a two-hundred day moving average price of €94.64.
MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It offers prescription medicines to treat cancer, multiple sclerosis, infertility, growth deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, as well as squamous cell carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.
Featured Story: Buyback
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.